SavedAdd your journal

Journals / Astım Allerji İmmünoloji / 2020 / Cilt: 18 - Sayı: 3

The Prevalence of Hypersensitivity Reactions to Antirheumatic Biological Agents and Results of the Skin Tests: Experience of a Tertiary Referral Allergy Center in Turkey

Ceyda TUNAKAN DALGIÇ
Figen Yargucu ZİHNİ
Gökten BULUT
Ali KÖKLÜDAĞ
Aytül Zerrin SİN
Pages
118–127
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The prevalence of HSRs to BAs was less than the ones mentioned in the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The use of biological agents (BAs) has increased dramatically for inflammatory diseases and this increase has led to a rise in hypersensitivity reactions (HSRs).
📊
Key Findings & Data:Four hundred sixty patients who received BAs between Jan 1st, 2015, and Jan 1st, 2016, were reviewed in this retrospective cross-sectional study.
💡
Conclusion & Impact:The prevalence of HSRs to BAs was less than the ones mentioned in the literature.
🔬Design:Review & Systematic Survey
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: The use of biological agents (BAs) has increased dramatically for inflammatory diseases and this increase has led to a rise in hypersensitivity reactions (HSRs). The symptoms and diagnostic tools for HSRs are not standardized. We aimed to analyze the prevalence of HSRs to anti-rheumatic BAs and to evaluate the usefulness of skin tests (STs) as a diagnostic tool. Materials and Methods: Our study was conducted at the Ege University Medical Faculty, Department of Internal Medicine, Division of Allergy and Clinical Immunology and Division of Rheumatology, Izmir, Turkey. Four hundred sixty patients who received BAs between Jan 1st, 2015, and Jan 1st, 2016, were reviewed in this retrospective cross-sectional study. The prevalence of HSRs was retrospectively evaluated. Ten patients with HSRs were evaluated with STs containing commercially available culprit drugs. The data was collected from hospital records. The age, sex, atopic diseases, primary rheumatic diseases, and anti-rheumatic therapies of the patients were recorded.Results: Two hundred fifty patients were treated with rituximab (RTX), 45 with infliximab, 40 with tocilizumab (TOC), 36 with golimumab, 35 with etanercept, 34 with abatacept, 15 with certolizumab, and 5 with adalimumab. Fifty reactions with RTX and two reactions with TOC were infusion-related (IRRs). Ten HSRs were observed. Eight patients had immediate (7 immediate systemic reactions and 1 local injection site reactions), and 2 had late-onset cutaneous reactions. We detected the ratio of IRRs as 11.3%, immediate HSRs as 1.73%, IgE-mediated reactions as 1.08%, and anaphylaxis as 0.86%. STs were positive in 5 of 8 patients with immediate HSRs. Four of them had anaphylaxis, and remarkably, 3 of these had positive STs. None of the ten patients had high levels of specific IgE and only four had atopic diseases. Total IgE levels were not high and specific IgE levels were not positive in the presence of HSR to BAs (p=0.039). Conclusion: Five of the 8 (62.5%) patients with immediate reactions had positive STs, which suggested IgE-mediated reactions. The prevalence of HSRs to BAs was less than the ones mentioned in the literature.

🔖

Cite This Article

DALGIÇ, C. T., ZİHNİ, F. Y., BULUT, G., KÖKLÜDAĞ, A., SİN, A. Z. (2020). The Prevalence of Hypersensitivity Reactions to Antirheumatic Biological Agents and Results of the Skin Tests: Experience of a Tertiary Referral Allergy Center in Turkey. Astım Allerji İmmünoloji, Cilt: 18 - Sayı: 3, 118–127. https://ajindex.com/articles/351220

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Lee SJ, Kavanaugh A. Adverse reactions to biologic agents: Focus on autoimmune disease therapies. J Allergy Clin Immunol 2005; 116(4):900-5
  2. Isabwe GAC, Neuer MG, de las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J Allergy Clin Immunol 2018;142:159-70
  3. Picard M, Galvao VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract 2017;5:600-9
  4. Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunol 2015;4:e39
  5. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009;124:1259-66
  6. Levin AS, Otani IM, Lax T, Hochberg E, Banerji A. Reactions to rituximab in an outpatient infusion center: A 5-year review. J Allergy Clin Immunol Pract 2017;5:107-13.e1
  7. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy 2014;69:420-37
  8. Bavbek S, Ataman S, Akinci A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 2015;3:629-32
  9. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73
  10. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 2008;18(5): 335-42
  11. Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol 2016;137(6):1674- 80
  12. Galva˜o VR, Castells MC. Hypersensitivity to biological agents updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract 2015;3(2):175-85
  13. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor-alpha receptor: Fc fusion protein. Arch Dermatol 2001;137(7):893-9
  14. Luheshi G, Rothwell N. Cytokines and fever. Int Arch Allergy Immunol 1996;109(4):301-7
  15. Santos RB, Galvão VR. Monoclonal antibodies hypersensitivity: Prevalence and management. Immunol Allergy Clin North Am 2017;37(4):695-711
  16. Brockow K, Rom